Pharma strategy is getting rewritten in real time—and most teams are still reading last quarter’s map.
Here’s the uncomfortable truth: “market entry intelligence” isn’t a nice-to-have anymore. It’s the difference between winning a launch and paying for…
Generic and biosimilar launches don’t happen on a calendar—they happen when exclusivity breaks.
That’s the uncomfortable truth for payers, pharmacy benefit managers, and brand teams alike: the “right time” to switch isn’t a gut feel. It’s a data ques…
20 years on paper. The real story is longer—and it matters.
Most people hear “drug patent duration” and assume the clock starts, runs for 20 years, and ends cleanly. In practice, the timeline is more like a relay race—multiple legal instruments, regula…
20 Years on Paper: The Real Guide to Drug Patent Duration in the United States Read Post »
South America’s drug patent map is no longer a “nice-to-know.” It’s a competitive advantage.
If you’re building a pipeline, negotiating partnerships, or planning launches, you can’t afford to treat patent landscapes as a single global spreadsheet. The …
South American Drug Patents: The Definitive Country-by-Country Breakdown Read Post »
Specialty pharmacy contracts don’t wait for patent cliffs. Biopharma should treat them like a pre-launch asset—because they are.
In specialty drugs, the real race often starts before the drug is even fully “available” in the market.
If you’re a biophar…
Pharma buyers are leaving money on the table—and taking avoidable risk—by ignoring one of the most practical tools in their procurement toolkit: Paragraph IV due diligence.
Here’s the uncomfortable truth: many procurement teams treat Paragraph IV filin…
Paragraph IV Filings: The Procurement Due Diligence Tool Most Pharma Buyers Ignore Read Post »
Drug patents in Asia-Pacific: the protection you think you have vs. the protection you actually get
If you’re building a pipeline, underwriting risk, or pricing a launch strategy, “patent life” is one of those phrases that sounds precise—until you look…
Drug patent expiry dates aren’t just legal milestones—they’re commercial calendars. And most teams treat them like a compliance checkbox instead of a revenue engine.
Here’s the agitation: if you’re waiting until a patent is “about to expire” to build y…
Turn Drug Patent Expiry Dates Into Your Next Sales Campaign Read Post »
The smarter monopoly isn’t a patent. It’s orphan exclusivity.
If you want to understand why drug prices stay sticky—even after patents expire—look past the headline-grabbing “patent cliff” and into a quieter mechanism: orphan drug exclusivity. It’s d…
The Smarter Monopoly: Orphan Drug Exclusivity vs. Standard Drug Patents Read Post »
Sell Before the Cliff: A Business Development Playbook for Sterile Manufacturing Suppliers Targeting Biologic LOE
Biologics don’t just “end”—they cliff. And when loss of exclusivity (LOE) hits, the market doesn’t politely wait for your pipeline to catc…